An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals
Summary: Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We devel...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-02-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004223000263 |
| _version_ | 1797903376984309760 |
|---|---|
| author | Anna Offersgaard Carlos Rene Duarte Hernandez Shan Feng Pavel Marichal-Gallardo Kenn Holmbeck Anne Finne Pihl Carlota Fernandez-Antunez Garazi Peña Alzua Katrine Top Hartmann Long V. Pham Yuyong Zhou Karen Anbro Gammeltoft Ulrik Fahnøe Uffe Vest Schneider Gabriel Kristian Pedersen Henrik Elvang Jensen Jan Pravsgaard Christensen Santseharay Ramirez Jens Bukh Judith Margarete Gottwein |
| author_facet | Anna Offersgaard Carlos Rene Duarte Hernandez Shan Feng Pavel Marichal-Gallardo Kenn Holmbeck Anne Finne Pihl Carlota Fernandez-Antunez Garazi Peña Alzua Katrine Top Hartmann Long V. Pham Yuyong Zhou Karen Anbro Gammeltoft Ulrik Fahnøe Uffe Vest Schneider Gabriel Kristian Pedersen Henrik Elvang Jensen Jan Pravsgaard Christensen Santseharay Ramirez Jens Bukh Judith Margarete Gottwein |
| author_sort | Anna Offersgaard |
| collection | DOAJ |
| description | Summary: Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralizing antibodies in mice; moreover, lyophilized antigen was immunogenic. Following homologous challenge, I-SARS-CoV-2 immunized hamsters were protected against disease and lung pathology. In contrast with reports for widely used vaccines, hamster plasma similarly neutralized the homologous and the Delta (B.1.617.2) variant viruses, whereas the Omicron (B.1.1.529) variant was neutralized less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage. |
| first_indexed | 2024-04-10T09:31:56Z |
| format | Article |
| id | doaj.art-5be313e70944483e85a0601f5bf5dfe3 |
| institution | Directory Open Access Journal |
| issn | 2589-0042 |
| language | English |
| last_indexed | 2024-04-10T09:31:56Z |
| publishDate | 2023-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj.art-5be313e70944483e85a0601f5bf5dfe32023-02-19T04:26:41ZengElsevieriScience2589-00422023-02-01262105949An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animalsAnna Offersgaard0Carlos Rene Duarte Hernandez1Shan Feng2Pavel Marichal-Gallardo3Kenn Holmbeck4Anne Finne Pihl5Carlota Fernandez-Antunez6Garazi Peña Alzua7Katrine Top Hartmann8Long V. Pham9Yuyong Zhou10Karen Anbro Gammeltoft11Ulrik Fahnøe12Uffe Vest Schneider13Gabriel Kristian Pedersen14Henrik Elvang Jensen15Jan Pravsgaard Christensen16Santseharay Ramirez17Jens Bukh18Judith Margarete Gottwein19Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkBioprocess Engineering, Max Planck Institute for Dynamics of Complex Technical Systems, 39106 Magdeburg, GermanyCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkDepartment of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg C, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkDepartment of Clinical Microbiology, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, DenmarkCenter for Vaccine Research, Statens Serum Institut, 2300 Copenhagen S, DenmarkDepartment of Veterinary and Animal Sciences, University of Copenhagen, 1870 Frederiksberg C, DenmarkDepartment of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, DenmarkCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital–Hvidovre, 2650 Hvidovre, Denmark; CO-HEP, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen N, Denmark; Corresponding authorSummary: Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralizing antibodies in mice; moreover, lyophilized antigen was immunogenic. Following homologous challenge, I-SARS-CoV-2 immunized hamsters were protected against disease and lung pathology. In contrast with reports for widely used vaccines, hamster plasma similarly neutralized the homologous and the Delta (B.1.617.2) variant viruses, whereas the Omicron (B.1.1.529) variant was neutralized less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.http://www.sciencedirect.com/science/article/pii/S2589004223000263ImmunologyImmune responseVirology |
| spellingShingle | Anna Offersgaard Carlos Rene Duarte Hernandez Shan Feng Pavel Marichal-Gallardo Kenn Holmbeck Anne Finne Pihl Carlota Fernandez-Antunez Garazi Peña Alzua Katrine Top Hartmann Long V. Pham Yuyong Zhou Karen Anbro Gammeltoft Ulrik Fahnøe Uffe Vest Schneider Gabriel Kristian Pedersen Henrik Elvang Jensen Jan Pravsgaard Christensen Santseharay Ramirez Jens Bukh Judith Margarete Gottwein An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals iScience Immunology Immune response Virology |
| title | An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals |
| title_full | An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals |
| title_fullStr | An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals |
| title_full_unstemmed | An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals |
| title_short | An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals |
| title_sort | inactivated sars cov 2 vaccine induced cross neutralizing persisting antibodies and protected against challenge in small animals |
| topic | Immunology Immune response Virology |
| url | http://www.sciencedirect.com/science/article/pii/S2589004223000263 |
| work_keys_str_mv | AT annaoffersgaard aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT carlosreneduartehernandez aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT shanfeng aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT pavelmarichalgallardo aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT kennholmbeck aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT annefinnepihl aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT carlotafernandezantunez aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT garazipenaalzua aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT katrinetophartmann aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT longvpham aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT yuyongzhou aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT karenanbrogammeltoft aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT ulrikfahnøe aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT uffevestschneider aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT gabrielkristianpedersen aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT henrikelvangjensen aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT janpravsgaardchristensen aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT santseharayramirez aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT jensbukh aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT judithmargaretegottwein aninactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT annaoffersgaard inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT carlosreneduartehernandez inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT shanfeng inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT pavelmarichalgallardo inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT kennholmbeck inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT annefinnepihl inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT carlotafernandezantunez inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT garazipenaalzua inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT katrinetophartmann inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT longvpham inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT yuyongzhou inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT karenanbrogammeltoft inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT ulrikfahnøe inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT uffevestschneider inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT gabrielkristianpedersen inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT henrikelvangjensen inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT janpravsgaardchristensen inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT santseharayramirez inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT jensbukh inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals AT judithmargaretegottwein inactivatedsarscov2vaccineinducedcrossneutralizingpersistingantibodiesandprotectedagainstchallengeinsmallanimals |